Late Wednesday, Ambit Biosciences Inc. disclosed an S-1 filing with the SEC for an initial public offering (IPO) of its common stock, expected to trade on the Nasdaq market under the symbol "AMBI." The company is seeking to raise up to $57.5 million, though the number of shares and price range were not yet determined. Read More
Tesaro Inc. topped up its cash with a $75 million public offering to support development and clinical trials of its oncology pipeline products. The company expects net proceeds of $69.7 million to support operations for the next 12 months. Read More
LONDON – While the development of biosimilars – biological medicines designed to be very similar to ones that have already been approved for clinical use – is really still in its infancy, people already are looking to the future and considering what sorts of molecules will come next. Read More
• Novelos Therapeutics, Inc., of Madison, Wisc., said it closed a public offering of 11 million units at $0.50 per unit for gross proceeds of $5.5 million. Read More
• Spectrum Pharmaceuticals Inc., of Henderson, Nev., reported that its total GAAP consolidated revenue was $267.7 million for the 12-month period ending Dec. 31, 2012, representing a 38.7 percent increase from the $193 million in consolidated revenue recorded in the same period of 2011. Read More
• ConfometRx, of Palo Alto, Calif., signed a research agreement with UCB SA, of Brussels, Belgium, to pursue the discovery of medicines addressing unmet medical needs in neuroscience. Under the two-year, multi-target agreement, the companies will leverage structural biology to gain insight into G-protein coupled receptor modulation, with an eye toward the design of differentiated drugs. Read More
• Immune Pharmaceuticals Ltd., of Herzliya-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., said Immune is initiating a Phase II double-blind placebo-controlled study with its lead drug bertilimumab in patients with moderate-to-severe ulcerative colitis. Read More
• Cumberland Pharmaceuticals Inc., of Nashville, Tenn., partnered with Sandor Medicaids Pvt Ltd., of Hyderabad, India, to commercialize Caldolor (ibuprofin) injection in India for treatment of pain and fever. Read More
• Pfizer Inc., of New York, said top-line results from a Phase III study showed Lyrica (pregabalin) capsules CV were as effective as levetiracetam (Keppra, UCB SA) as adjunctive therapy for refractory partial onset seizures in adults with epilepsy. Read More
